2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2323

Predictors of Mortality in Patients with Hip Fragility Fracture
Abstract Number: 2352

Predictors of Patient and Physician Perceptions of Gout Disease Activity
Abstract Number: 593

Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Abstract Number: 1494

Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Abstract Number: 2324

Predictors of Refracture in Patients with Hip Fragility Fracture
Abstract Number: 400

Predictors of Response to a Single Intra-Articular Injection of Mannitol-Modified Cross-Linked Hyaluronic Acid (HANOX-M-XL) in Patients with First Metatarsophalangeal Joint Osteoarthritis (hallux rigidus)
Abstract Number: 2499

Predictors of Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-Years Follow-up Study
Abstract Number: 2621

Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Abstract Number: 798

Predominant Fasciitis and Mild Intramuscular Edema on Muscle Magnetic Resonance Imaging in Scleroderma-Associated Myopathy
Abstract Number: 2288

Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
Abstract Number: 1852

Pregnancy in Lupus: 17-Year U.S. Nationwide Trend in Obstetric and Maternal Outcomes
Abstract Number: 2704

Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis
Abstract Number: 2430

Pregnancy in Women with Ankylosing Spondylitis Is Not Associated with Poor Obstetric Outcomes: Analysis of Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 2420

Pregnancy Outcome and Perinatal Complications of Neonate Born to Mothers with Juvenile Idiopathic Arthritis in Asia
Abstract Number: 2435

Pregnancy Outcomes Among Women with Rare Autoimmune Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].